Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.
about
INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaBNo p16INK4A/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas.Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancerOrthotopic models of human pancreatic cancer.Strategies for the detection of disease genes in pancreatic cancer.Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human diseaseGenetic progression and divergence in pancreatic carcinomaGenetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas.The CDKN2A (p16) gene and human cancer.Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.Genetic alterations in pancreatic cancer.Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpointInhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functionsFlavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3β/NF-κB signaling cascade.Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation.Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras.Overexpression of p53 protein during pancreatitis.Detection of oncogenes in chronic pancreatitis.Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity.Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial.DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer.Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study.The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect
P2860
Q22009941-2E144E9A-E668-4481-9E68-FE209C6771A9Q30321283-FC06A4E0-10F7-4364-B363-CDFD2CD3A5BEQ33628253-2E68F094-1EAF-4054-95BA-C7E051B5BC2BQ33692987-5D2EC88D-0F7F-4EF1-BFCA-2226DE8F0897Q33692996-E91EFA7B-62AC-441E-A67C-C74F945DC43EQ34446744-E15C7AE8-C157-4A8F-B761-86CC7BFC44F3Q35076746-2E1BA254-9FDE-4435-8212-A2CDBBB20A17Q35745480-65453E70-2F40-464E-8C85-66799F88C661Q35764095-0634B2F9-CCAD-488D-AD21-EDD24B82E21CQ36437816-00215639-C8BB-4CFC-90C4-8DFE35C672A6Q36609890-2683D6A9-2B81-4015-8731-AC8BB61F07C3Q36622459-2D47E229-FD33-4C9A-BCCB-C95B2F081E31Q36921331-8854E5DB-A0CB-4620-A895-113C0D781D75Q37109795-A5E0A960-A531-43B6-BAB3-272151C8D652Q37377431-F9C08497-ACBD-4380-ABA3-0C8E5F472E6DQ39063127-5C77E2B4-BD25-425D-A8D2-286891EF0F00Q39110471-D0CE5451-8BB7-45D1-A91A-220E87096086Q39687238-D0A8632B-1745-4FBC-87BD-4DA10F69D376Q40887247-E97E7725-7CBD-4B48-98F9-2E24B4B619D1Q41911268-5D5405E7-28CE-4DF3-B68F-F9E7B1ECD87EQ42173126-41AB776D-6484-4DC7-A4CC-D18CADBE5325Q44006142-FCEA7184-992A-4700-B07E-0E279DF3A6A7Q44256491-0CE77F55-3C88-4290-8CCC-A739B43A6A69Q44317105-34B7D8D4-566E-4028-A5DC-DF3B37559345Q45876450-0DB20D54-109A-4C97-9DF9-D78941441065Q53923243-3C6F4E34-021A-440C-9A49-3F28D272C067Q54737674-CDBCA21B-687D-4665-A1F8-E0BE44960C59Q56893701-CAC7A1AA-AC49-4082-883F-9AA1B4C0FBB6
P2860
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@en
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@nl
type
label
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@en
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@nl
prefLabel
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@en
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@nl
P2093
P1433
P1476
Frequent codeletion of p16/MTS ...... p16/MTS1 in pancreatic tumors.
@en
P2093
Kalthoff H
Savitskaia N
Schmiegel W
P304
P356
10.1053/GAST.1996.V110.PM8613012
P407
P577
1996-04-01T00:00:00Z